Ken Griffin Evogene Ltd. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$0.61 - $0.82 $13,786 - $18,532	-22,600 Reduced 98.26%	400 $0
Q1 2024 May 15, 2024	BUY	$0.7 - $0.98 $16,099 - $22,540	23,000 New	23,000 $17,000
Q3 2023 Nov 14, 2023	SELL	$0.58 - $1.41 $3,132 - $7,614	-5,400 Reduced 87.1%	800 $0
Q2 2023 Aug 14, 2023	SELL	$0.56 - $1.2 $1,008 - $2,160	-1,800 Reduced 22.5%	6,200 $6,000
Q1 2023 May 15, 2023	SELL	$0.59 - $0.86 $177 - $258	-300 Reduced 3.61%	8,000 $5,000
Q4 2022 Feb 14, 2023	SELL	$0.61 - $8.13 $8,113 - $108,129	-13,300 Reduced 61.57%	8,300 $5,000
Q3 2022 Nov 14, 2022	SELL	$0.73 - $8.65 $12,556 - $148,780	-17,200 Reduced 44.33%	21,600 $18,000

117K

Ticker EVGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,202,000
Market Cap $61.4M
Description
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.